DoNotAge SIRT6Activator Is Used in NUS PROMETHEUS Healthy-Ageing Trial

The most important fact about the DoNotAge–PROMETHEUS connection is precise: a peer-reviewed 2026 GeroScience protocol names DoNotAge SIRT6Activator® as the fucoidan used in an eight-week human healthy-ageing study at the National University of Singapore. The study used SIRT6Activator at 2.4 g/day as one component of a much larger personalised programme.

That is meaningful human-research use of the DoNotAge ingredient. It is not, however, a standalone clinical trial proving that SIRT6Activator by itself improves biological age, lifespan or any other clinical outcome. PROMETHEUS was designed as a small, single-arm feasibility and exploratory study of a multimodal intervention.

PROMETHEUS at a glance

Exactly where SIRT6Activator fits into PROMETHEUS

All participants received a set of fundamental interventions. According to the protocol, these included sleep and dietary recommendations, whey protein, creatine, 2.4 g/day of fucoidan identified as SIRT6Activator® from DoNotAge.org, supervised multicomponent exercise with exergaming, motivational interviewing and cognitive-behavioural strategies.

The programme then added personalised interventions according to each participant’s measured “gerotype” and response. Depending on baseline muscle mass, aerobic capacity and cognition, participants could receive urolithin A, NMN and/or a multivitamin-mineral supplement. The protocol also allowed mid-intervention adjustments. For example, ergothioneine could be added for inadequate cognitive improvement, while the fucoidan dose could be increased from 2.4 g/day to 3.6 g/day if the expected direction of change in immune function was not achieved.

This design is central to interpreting the study. PROMETHEUS asks whether a personalised package of lifestyle, exercise, behavioural and nutraceutical interventions is feasible and potentially useful—not whether one capsule or ingredient independently produces the programme’s outcomes.

What did PROMETHEUS measure?

The protocol describes outcomes across several systems rather than relying on a single “biological age” number. Primary assessments include feasibility and adherence plus changes in:

• Muscle function: VO₂peak and one-repetition maximum strength.
• Muscle mass: including ultrasound-based muscle measurements.
• Cognitive function: using the NIH Toolbox Fluid Cognition Composite.
• Immune function: including the CD4/CD8 T-cell ratio.

Secondary assessments span additional biological, clinical and digital ageing biomarkers. The paper makes clear that the small sample size was chosen for feasibility and preliminary, hypothesis-generating analysis rather than definitive efficacy testing.

A status discrepancy worth understanding

There is an important difference between the current public registry display and the peer-reviewed protocol.

The GeroScience paper states that recruitment began in July 2025, finished in December 2025, and that the final participant completed the last study visit on February 23, 2026. At the time the manuscript was prepared, the study was in the biomarker-measurement and analysis phase.

ClinicalTrials.gov, however, still displays NCT07451496 as Recruiting, with its last registry update dated March 5, 2026. The defensible interpretation is not to silently choose one label over the other: the peer-reviewed paper documents that participant visits had finished, while the public registry appears not to have been updated to reflect that operational status.

What does the study prove about DoNotAge SIRT6Activator?

At this stage, the protocol establishes several useful facts:

• DoNotAge SIRT6Activator was actually incorporated into an academic human study protocol.
• The paper specifies the study dose and identifies the material as fucoidan/SIRT6Activator from DoNotAge.org.
• DoNotAge supplied SIRT6Activator to the study.
• The programme was conducted through the NUS Academy for Healthy Longevity and received ethics approval from the NUS Institutional Review Board.

It does not establish that SIRT6Activator alone caused improvements in muscle, cognitive or immune outcomes. There was no SIRT6Activator-only arm, no SIRT6Activator placebo comparison and no design capable of separating the contribution of SIRT6Activator from the exercise, diet, sleep, creatine, whey protein, behavioural interventions or personalised supplements used alongside it.

Who funded the PROMETHEUS study?

This relationship also needs exact language. The protocol’s acknowledgements thank DoNotAge.org for providing SIRT6Activator. Its funding section states that the study was funded by the XPRIZE Foundation and the National University of Singapore.

So the accurate description is: DoNotAge supplied a study intervention; it is not identified in the protocol as the overall study funder.

What happened after the protocol was published?

The protocol was published in GeroScience on July 3, 2026. NUS Academy for Healthy Longevity later announced that Team NUS PROMETHEUS advanced in the XPRIZE Healthspan competition. That competition milestone is important for the programme, but it still should not be interpreted as a positive clinical efficacy result for SIRT6Activator itself.

Read the NUS PROMETHEUS XPRIZE update.

Why PROMETHEUS matters for the DoNotAge research record

From a DoNotAge evidence perspective, PROMETHEUS is stronger than a marketing claim because the relationship is documented in a peer-reviewed academic protocol. It shows that a named DoNotAge ingredient was selected for use in a human geroscience programme and identifies exactly how it was used.

The limitation is equally important: the research question is multimodal. If PROMETHEUS ultimately reports favourable whole-programme outcomes, those results would support the combined precision-geromedicine strategy. They would not automatically become a standalone clinical efficacy trial of SIRT6Activator.

Primary sources

• GeroScience — PROMETHEUS clinical trial protocol
• PubMed record — PROMETHEUS protocol
• ClinicalTrials.gov — NCT07451496
• DoNotAge research, clinical trials and grants tracker

PROMETHEUS and SIRT6Activator FAQ

Is PROMETHEUS a clinical trial of DoNotAge SIRT6Activator?

SIRT6Activator is used in the human PROMETHEUS study, but PROMETHEUS is not a standalone SIRT6Activator efficacy trial. It tests a personalised multimodal programme containing many simultaneous interventions.

What SIRT6Activator dose was used?

The protocol specifies 2.4 g/day of fucoidan identified as SIRT6Activator® from DoNotAge.org as a fundamental intervention. The design allowed the fucoidan dose to increase to 3.6 g/day at mid-intervention if the expected direction of immune-function change was not achieved.

Did DoNotAge fund PROMETHEUS?

The paper states that DoNotAge supplied SIRT6Activator. It lists the XPRIZE Foundation and National University of Singapore as the study funders.

Have PROMETHEUS efficacy results been published?

The July 2026 GeroScience publication is a methods/protocol paper, not a final efficacy-results paper. It states that the study was in biomarker measurement and analysis after the final participant visit.

Why does ClinicalTrials.gov still say Recruiting?

The public registry still shows Recruiting, but the peer-reviewed protocol says recruitment finished in December 2025 and the final participant completed the last study visit on February 23, 2026. The registry therefore appears administratively behind the status described in the publication.